洛莫司汀-替莫唑胺对比替莫唑胺治疗MGMT甲基化胶质母细胞瘤的生活质量与神经认知功能:CeTeG/NOA-09随机三期试验
CeTeG/NOA-09试验显示,对于MGMT启动子甲基化的新诊断胶质母细胞瘤患者,洛莫司汀-替莫唑胺联合治疗较标准替莫唑胺显著延长总生存期。本报告分析该试验中健康相关生活质量(HRQOL)和神经认知功能(次要终点),结果显示联合治疗组HRQOL无显著损害,MMSE差异虽有利于替莫唑胺组但无临床相关性,神经认知测试组间无显著差异。
核心结论
- 洛莫司汀-替莫唑胺联合治疗未导致HRQOL和神经认知功能的系统性和临床相关改变,结合生存获益,提示对该人群存在长期净临床获益,支持其作为治疗选择。
研究设计与样本
- 随机、多中心、开放标签、三期试验,在德国17家大学医院招募18-70岁、KPS≥70%、新诊断、未接受化放疗的MGMT甲基化胶质母细胞瘤患者。
- 患者接受标准放疗(60 Gy)后按1:1随机分配至洛莫司汀-替莫唑胺联合组或标准替莫唑胺组,主要终点为总生存期。
- HRQOL(EORTC QLQ-C30和BN20)和神经认知功能(MMSE及NOA-07测试组合)为次要终点,在改良意向治疗人群(mITT,至少接受一剂化疗)中分析。
- 共141例患者随机分配,129例开始治疗并纳入mITT分析(替莫唑胺组63例,联合组66例)。
关键数值与推荐
- HRQOL临床相关阈值定义为≥10分,MMSE临床相关阈值定义为≥3分。
临床怎么用
- 对于MGMT启动子甲基化的新诊断胶质母细胞瘤患者,洛莫司汀-替莫唑胺联合治疗在生存获益的同时未牺牲HRQOL和神经认知功能,可作为治疗选项。
局限性
- 开放标签设计可能影响患者报告结局;HRQOL和神经认知功能为次要终点,部分测试随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CeTeG/NOA-09 trial showed significantly longer overall survival with combined lomustine-temozolomide therapy compared with standard temozolomide for patients with glioblastoma with methylated MGMT promoter. The trial also aimed to investigate the effect of lomustine-temozolomide therapy on health-related quality of life (HRQOL) and neurocognitive function, which we report here. METHODS: In this randomised, multicentre, open-label, phase 3 trial, newly diagnosed, chemoradiotherapy-naive patients with MGMT-methylated glioblastoma, aged 18-70 years, with a Karnofsky performance score of 70% or higher, were recruited and enrolled at 17 university hospitals in Germany. Patients received standard radiotherapy (60 Gy) and were randomly assigned (1:1, stratified by centre by allocating complete blocks of six to a centre, without masking) to either six 6-week courses of oral combined lomustine (100 mg/m2 on day 1) plus temozolomide (100-200 mg/m2 on days 2-6) or standard oral temozolomide (75 mg/m2 daily during radiotherapy plus six 4-week courses of temozolomide [150-200 mg/m2] on days 1-5, every 4 weeks). The primary endpoint was overall survival. HRQOL, assessed using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 and the EORTC brain cancer module (BN20); and neurocognitive function, assessed using the Mini Mental State Examination (MMSE), plus a neurocognitive test battery (NOA-07), including Trail Making Test A and B (TMT-A and B), working memory tests, and tests for lexical (Controlled Oral Word Association [COWA]) and semantic verbal fluency, were secondary endpoints analysed in the modified intention-to-treat population (mITT; all randomly assigned patients who received at least one dose of study chemotherapy). We used linear mixed-model analyses to investigate differences between treatment groups regarding HRQOL (clinically relevant ≥10 points) and MMSE scores (clinically relevant ≥3 points). The trial is registered with ClinicalTrials.gov, NCT01149109. FINDINGS: Between June 17, 2011 and April 8, 2014, 141 patients were randomly assigned and 129 patients began treatment and were included in the mITT population (63 in the temozolomide and 66 in the lomustine-temozolomide group). Median follow-up for HRQOL (the item global health) was 19·4 months (IQR 7·8-38·6), for MMSE was 15·3 months (4·1-29·6), and for COWA was 11·0 months (0-27·5). We found no significant impairment regarding any item of HRQOL in the lomustine-temozolomide group (difference between the groups for global health 0·30 [95% CI -0·23 to 0·83]; p=0·26). Differences in MMSE were in favour of the temozolomide group (difference -0·11 [95% CI -0·19 to -0·03]; p=0·0058) but were not clinically relevant (1·76/30 points over 4 years). We found no significant difference between the groups in any subtest of the neurocognitive test battery (difference for COWA 0·04 [95% CI -0·01 to 0·09]; p=0·14). INTERPRETATION: The absence of systematic and clinically relevant changes in HRQOL and neurocognitive function combined with the survival benefit of lomustine-temozolomide versus temozolomide alone suggests that a long-term net clinical benefit exists for patients with newly diagnosed glioblastoma with methylation of the MGMT promoter and supports the use of lomustine-temozolomide as a treatment option for these patients. FUNDING: German Federal Ministry of Education and Research.
引用
- Weller J, Tzaridis T, Mack F, et al. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2019. PMID: 31488360. doi:10.1016/S1470-2045(19)30502-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。